Picture loading failed.

Pre-Made Suptavumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Suptavumab (INN; development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-535-1mg 1mg 3090
GMP-Bios-ab-535-10mg 10mg Inquiry
GMP-Bios-ab-535-100mg 100mg Inquiry
GMP-Bios-ab-535-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Suptavumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody
INN Name Suptavumab
TargetRSV gpF
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesRegeneron Pharmaceuticals
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedRespiratory syncytial virus infections
Development TechVelocImmune Mouse;VelociGene